Travere Therapeutics, Inc. (TVTX)
43.33
+0.76
(+1.79%)
USD |
NASDAQ |
May 18, 13:20
Travere Therapeutics Research and Development Expense (Quarterly) : 57.09M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 341.62M |
| AbbVie, Inc. | 2.472B |
| Mirum Pharmaceuticals, Inc. | 97.84M |
| Anika Therapeutics, Inc. | 6.713M |
| BioCryst Pharmaceuticals, Inc. | 59.26M |